Table 1 Priming of MSC with cytokines and growth factors
From: Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies
Stimuli | Source MSC | Model/disease | In vivo/in vitro | Results | References |
|---|---|---|---|---|---|
IFN-γ and TNF-α | Bone marrow | – | In vitro | Induced chromatin remodeling in the IDO1 promoter. | [33] |
IFN-γ and TNF- α | Bone marrow | – | In vitro | Suppressed T cell proliferation by IDO upregulation and induced greater IL-10-secreting M2 macrophages differentiation. | [31] |
IFN-γ and TNF- α | – | – | In vitro | Increased factor H production. | [30] |
IFN-γ | Bone marrow | – | In vitro | Inhibited T cell effector function through the ligands for PD1 and Th1 cytokines production. | [20] |
IFN-γ | Bone marrow | – | In vitro | Retained the ability to inhibit the degranulation and proliferation of cytotoxic T cells post-thaw. | [24] |
IFN-γ | Bone marrow | – | In vitro | Reestablished immunosuppressive effect on T-cell proliferation and did not upregulate HLA-DR of senescent MSC. | [25] |
IFN-γ | Bone marrow | DSS-induced colitis model | In vitro/in vivo (mice) | Attenuated development of colitis, reduced pro-inflammatory cytokine levels in colon and increased migration potential. | [26] |
IFN-γ | Umbilical cord | Healthy donor/tissue | In vitro | Increased suppression of NK cells and reduced NK-mediated cytotoxicity. | [21] |
IL-1α and IL-1β | Bone marrow | – | In vitro | Increased secretion of G-CSF through IL-1 receptor type 1, reduced the secretion of IL-6 and TNF-α in microglial cells. | [53] |
IL-1β | Umbilical cord | DSS-induced colitis model | In vitro/in vivo (mice) | Attenuated the development of murine colitis, increased migration potential to inflammatory sites by CXCR4 upregulation. | [52] |
IL-1β | Bone marrow | Healthy donor/tissue | In vitro | Induced the secretion of trophic factors and adhesion to ECM components; enhanced recruitment of leucocytes by NF-κB pathway. | [51] |
FGF-2 | Dental pulp | Subcutaneous implantation of priming MSCs encapsulated in a 3D collagen matrix | In vitro/in vivo (mice) | Increased VEGF and HGF secretion and improved vascularization in vivo. | [56] |
TNF-α and LPS | Bone marrow | – | In vitro | Increased alkaline phosphate activity and bone mineralization. | [50] |
IL-17A | Bone marrow | – | In vitro | Increased suppressive potential of T cell proliferation correlated with increased IL-6, inhibited surface CD25 and Th1 cytokines expression, and induced iTregs. | [164] |